RESUMO
This review considers the stages of the development of synthetic peptide vaccines against infectious agents, novel approaches and technologies employed in this process, including bioinformatics, genomics, proteomics, large-scale peptide synthesis, high-throughput screening methods, the use of transgenic animals for modelling human infections. An important role for the development and selection of efficient adjuvants for peptide immunogens is noted. Examples of synthetic peptide vaccine developments against three infectious diseases (malaria, hepatitis C, and foot-and-mouth disease) are given.
Assuntos
Febre Aftosa/prevenção & controle , Hepatite C/prevenção & controle , Vacinas Antimaláricas/imunologia , Malária/prevenção & controle , Peptídeos/imunologia , Vacinas contra Hepatite Viral/imunologia , Animais , Animais Geneticamente Modificados , Febre Aftosa/imunologia , Hepatite C/imunologia , Humanos , Malária/imunologia , Vacinas Antimaláricas/síntese química , Vacinas Antimaláricas/farmacologia , Peptídeos/síntese química , Peptídeos/farmacologia , Vacinas Sintéticas/imunologia , Vacinas Sintéticas/farmacologia , Vacinas contra Hepatite Viral/síntese química , Vacinas contra Hepatite Viral/farmacologiaRESUMO
Peptide RHDSGY that represents the fragment of human beta-amyloid Zn-binding site and its isomers RH(D-Asp)SGY and RH(beta-Asp)SGY have been prepared by solid-phase synthesis and analysed by HPLC and various mass-spectrometric methods. The problem of low yield of peptide RHDSGY and its isomers attributed to 9-fluorenylmethoxycarbonyl (Fmoc)-amino acids and/or formation of side-products as RH(Asp-imide)SGY and RHDSGY (instead of RH(beta-Asp)SGY) was solved via selection of reagents for the removal of Fmoc groups from the growing peptide chain.